The current charitable-PAP product list limits Ozempic injection to uninsured patients; no Ozempic tablet, Rybelsus or Wegovy PAP eligibility is inferred. Shared access support and self-pay home delivery are separate routes. The program must confirm exact formulation and eligibility.
HCP prescription call-in and published home-delivery questions/support. The current FAQ also directs damaged-package recipients to this same number.
Fax
855-251-0222
HCP prescription submission for Novocare home delivery, explicitly published by the current HCP page and corroborated in NPPES. Not a charitable-PAP application fax.
Confirm the exact product or service National contact — confirm product and location
Mailing addressLifefill I, LLC
1407 Broadway, Room 1910
New York, NY 10018-2874
NPPES registered MAILING address only; registry correspondence location, not a published patient-support, PAP or prescription-intake destination.
Physical address12639 W Explorer Dr, Ste 125
Boise, ID 83713-1887
Prescribing-system / EHR directory location published with NPI 1225959968 and NCPDP 1311961, corroborated as LOCATION in NPPES. Walk-in service and mailed-prescription intake are not established.
Current official page identifies Lifefill I, LLC d/b/a Novocare and pharmacy services powered by BlinkRx. Separate self-pay home-delivery program for Ozempic and Wegovy; no Rybelsus association, charitable-PAP eligibility, coverage, price, walk-in service or license status inferred. Earlier CoAssist Orlando prescription, case-manager and damaged-delivery proposals are superseded by this current page and are not imported.
Shared diabetes access/affordability support; not the separate charitable-PAP account line.
Published hours
Monday–Friday 08:00-23:00; Saturday 11:00-19:00, Eastern Standard Time as published. Seasonal time-zone handling unverified.
Product, plan and location
Confirm the exact product or service National contact — confirm product and location
Mailing address
Not researched for this route
Diabetes support only. Product names also appear in the current official diabetes navigation; no formulation, coverage or PAP eligibility follows from that association.